Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 10 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

10%

1 trials in Phase 3/4

Results Transparency

0 of 1 completed trials have results

Key Signals

3 recruiting

Enrollment Performance

Analytics

N/A

5(71.4%)

Phase 2

1(14.3%)

Phase 3

1(14.3%)

7Total

N/A(5)

Phase 2(1)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (10)

Showing 10 of 10 trials

NCT06960005Not ApplicableEnrolling By Invitation

ThyMoves: Screening and Exercise to Improve Muscle, Enhance Quality of Life, and Reduce Fall Risk in Thyroid Disease

Role: collaborator

NCT07373392Not ApplicableNot Yet Recruiting

Effects of LP-LDL® on Lipid Metabolism, Glycemic Control, Inflammatory Markers, and Cognitive Function in Individuals With Prediabetes and Diabetes Mellitus

Role: collaborator

NCT04916132Recruiting

Diabetic Nephropathy in People With Diabetes. Prevalence and Predictive Factors

Role: collaborator

NCT06134934Not ApplicableActive Not Recruiting

TeleCare North Diabetes

Role: collaborator

NCT06903728Not ApplicableNot Yet Recruiting

National Trial of CGM in Pregnant Women With Type 2 Diabetes

Role: collaborator

NCT06906081Phase 2Recruiting

Finerenone Treatment for Diabetic Cardiovascular Autonomic Neuropathy: the FibroCAN Study

Role: collaborator

NCT06082063Phase 3Recruiting

Multifactorial Intervention to Reduce Cardiovascular Disease in Type 1 Diabetes

Role: collaborator

NCT05678712Not ApplicableCompleted

Improved Glycemic Control in Diabetic Patients in Hemodialysis Using Continuous Glucose Monitoring (CGM)

Role: collaborator

NCT05673837Unknown

the Type ONe dIabetic Bone Collaboration Study

Role: collaborator

NCT04623697Unknown

Covid-19 Infection and New Onset Type 1 Diabetes

Role: collaborator

All 10 trials loaded